Off-label use of rituximab for systemic lupus erythematosus in Europe.


Ryden-Aulin M., Boumpas D., Bultink I., Rubio J. L. C., Caminal-Montero L., Castro A., ...More

Lupus science & medicine, vol.3, no.1, 2016 (Scopus) identifier identifier identifier

Abstract

Objectives: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy.